EP2480225A4 - DERMAL FORMULATIONS FROM DP2 RECEPTOR ANTAGONISTS - Google Patents

DERMAL FORMULATIONS FROM DP2 RECEPTOR ANTAGONISTS

Info

Publication number
EP2480225A4
EP2480225A4 EP10805005.5A EP10805005A EP2480225A4 EP 2480225 A4 EP2480225 A4 EP 2480225A4 EP 10805005 A EP10805005 A EP 10805005A EP 2480225 A4 EP2480225 A4 EP 2480225A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
dermal formulations
dermal
formulations
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10805005.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2480225A2 (en
Inventor
John Howard Hutchinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panmira Pharmaceuticals LLC
Original Assignee
Panmira Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panmira Pharmaceuticals LLC filed Critical Panmira Pharmaceuticals LLC
Publication of EP2480225A2 publication Critical patent/EP2480225A2/en
Publication of EP2480225A4 publication Critical patent/EP2480225A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP10805005.5A 2009-07-31 2010-07-28 DERMAL FORMULATIONS FROM DP2 RECEPTOR ANTAGONISTS Withdrawn EP2480225A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23058509P 2009-07-31 2009-07-31
PCT/US2010/043599 WO2011014588A2 (en) 2009-07-31 2010-07-28 Dermal formulations of dp2 receptor antagonists

Publications (2)

Publication Number Publication Date
EP2480225A2 EP2480225A2 (en) 2012-08-01
EP2480225A4 true EP2480225A4 (en) 2013-05-01

Family

ID=43503080

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10805005.5A Withdrawn EP2480225A4 (en) 2009-07-31 2010-07-28 DERMAL FORMULATIONS FROM DP2 RECEPTOR ANTAGONISTS

Country Status (11)

Country Link
US (1) US20120184493A1 (zh)
EP (1) EP2480225A4 (zh)
JP (1) JP2013500979A (zh)
KR (1) KR20120046762A (zh)
CN (1) CN102596193A (zh)
AR (1) AR077435A1 (zh)
CA (1) CA2768586A1 (zh)
SG (1) SG177736A1 (zh)
TW (1) TWI428315B (zh)
UY (1) UY32820A (zh)
WO (1) WO2011014588A2 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150072963A1 (en) * 2006-06-16 2015-03-12 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
EP2037967B1 (en) 2006-06-16 2016-12-07 The Trustees Of The University Of Pennsylvania Prostaglandin d2 receptor antagonists for treating androgenetic alopecia
CN101903338A (zh) 2007-12-19 2010-12-01 安姆根有限公司 用作炎症调节剂的苯基乙酸衍生物
BRPI0907364A2 (pt) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
JP2011526281A (ja) 2008-06-24 2011-10-06 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のシクロアルカン［ｂ］インドールアンタゴニスト
UY31956A (es) 2008-07-03 2010-01-29 Amira Pharmaceuticals Inc Antagonistas de heteroalquilo de receptores de prostaglandina d2
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
CN102596199A (zh) 2009-07-31 2012-07-18 潘米拉制药公司 Dp2受体拮抗剂的眼用医药组合物
CN102596902A (zh) 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途
EP2521713A4 (en) 2010-01-06 2013-10-02 Panmira Pharmaceuticals Llc ANTAGONIST OF DP2 AND ITS USES
RU2013104506A (ru) 2010-07-05 2014-08-10 Актелион Фармасьютиклз Лтд 1-фенилзамещенные производные гетероциклила и их применение в качестве модуляторов рецептора простагландина d2
KR20140107550A (ko) 2011-12-21 2014-09-04 액테리온 파마슈티칼 리미티드 헤테로시클릴 유도체 및 프로스타글란딘 ｄ2 수용체 조절제로서의 그의 용도
CN108938441A (zh) * 2012-03-21 2018-12-07 宾夕法尼亚大学理事会 用于调节毛发生长的组合物和方法
WO2014006585A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
FR3000399B1 (fr) * 2012-12-31 2015-03-27 Galderma Res & Dev Utilisation topique du laropiprant pour le traitement de la rosacee
WO2014159771A1 (en) * 2013-03-13 2014-10-02 The Regents Of The University Of California Prevention of rosacea inflammation
SI3119779T1 (sl) * 2014-03-17 2018-10-30 Idorsia Pharmaceuticals Ltd Derivati azaindolocetne kisline in njihova uporaba kot modulatorji prostaglandinskega receptorja D2
US20180021302A1 (en) * 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
RU2630775C2 (ru) * 2015-11-13 2017-09-13 Федеральное государственное унитарное предприятие "Институт химических реактивов и особо чистых химических веществ Национального исследовательского центра "Курчатовский институт" 2-арил-1,3-тиазолидин-4-карбоновые кислоты, обладающие противоопухолевой активностью
JP7122499B2 (ja) * 2016-06-03 2022-08-22 幸久 村田 がん転移阻害剤
KR20210008223A (ko) 2019-07-11 2021-01-21 제이투에이치바이오텍 (주) 탈모증의 치료 또는 개선을 위한 화합물 및 이들의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058164A2 (en) * 2002-12-20 2004-07-15 Tularik, Inc. Asthma and allergic inflammation modulators
WO2005095397A1 (en) * 2004-03-11 2005-10-13 Actelion Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
WO2007146838A2 (en) * 2006-06-09 2007-12-21 Icos Corporation Substituted phenyl acetic acids as dp-2 antagonists
WO2010037054A2 (en) * 2008-09-29 2010-04-01 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004182657A (ja) * 2002-12-04 2004-07-02 Eisai Co Ltd Ｈｄｌレベル上昇促進剤
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US7405302B2 (en) * 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
BRPI0907364A2 (pt) * 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058164A2 (en) * 2002-12-20 2004-07-15 Tularik, Inc. Asthma and allergic inflammation modulators
WO2005095397A1 (en) * 2004-03-11 2005-10-13 Actelion Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
WO2007146838A2 (en) * 2006-06-09 2007-12-21 Icos Corporation Substituted phenyl acetic acids as dp-2 antagonists
WO2010037054A2 (en) * 2008-09-29 2010-04-01 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S. A. BOEHME ET AL: "Antagonism of CRTH2 ameliorates chronic epicutaneous sensitization-induced inflammation by multiple mechanisms", INTERNATIONAL IMMUNOLOGY, vol. 21, no. 1, 1 January 2008 (2008-01-01), pages 1 - 17, XP055052313, ISSN: 0953-8178, DOI: 10.1093/intimm/dxn118 *

Also Published As

Publication number Publication date
TWI428315B (zh) 2014-03-01
UY32820A (es) 2011-01-31
CN102596193A (zh) 2012-07-18
CA2768586A1 (en) 2011-02-03
WO2011014588A2 (en) 2011-02-03
US20120184493A1 (en) 2012-07-19
WO2011014588A3 (en) 2011-06-23
AR077435A1 (es) 2011-08-24
TW201107293A (en) 2011-03-01
JP2013500979A (ja) 2013-01-10
EP2480225A2 (en) 2012-08-01
KR20120046762A (ko) 2012-05-10
SG177736A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
EP2480225A4 (en) DERMAL FORMULATIONS FROM DP2 RECEPTOR ANTAGONISTS
EP2461809A4 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
HK1188211A1 (zh) 受體拮抗劑
PL2453895T3 (pl) (+)-morfinany jako antagonisty receptora toll-like 9 i ich zastosowania terapeutyczne
GB2475121B (en) Structure of spraying device
ZA201202029B (en) Androgen receptor antagonists and uses thereof
SG10201404662YA (en) Dp2 antagonist and uses thereof
EP2427430A4 (en) 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS
IL215690A0 (en) Thiazole derivatives and their use as p2y12 receptor antagonists
IL269369A (en) The vehicles are improved
EP2582715A4 (en) GROWTH HORMONE SECRETAGOGUE RECEPTOR ANTAGONISTS AND USES THEREOF
IL217526A0 (en) Carbocyclic glyt1 receptor antagonists
EP2451281A4 (en) ANTAGONISTS OF OREXIN RECEPTORS BASED ON TETRAHYDRONAPHTHYRIDINE
EP2437601A4 (en) BIS-PYRIDYLPYRIDONE AS MELANIN CONCENTRATION HORMONE RECEPTOR-1 ANTAGONISTS
IL214731A0 (en) Uses of nk receptor antagonists
EP2437598A4 (en) BIS-PYRIDYLPYRIDONES AS MELANGE-CONCENTRATION HORMONE RECEPTOR ANTAGONISTS
EP2437599A4 (en) BIS-PYRIDYLPYRIDONE AS MELANIN CONCENTRATION HORMONE RECEPTOR-1 ANTAGONISTS
GB0915480D0 (en) Stable formulation of factor viii
EP2437600A4 (en) BIS-PYRIDYLPYRIDONE AS MELANIN CONCENTRATION HORMONE RECEPTOR-1 ANTAGONISTS
HK1163452A1 (en) Disintegrable formulations of lanthanum carbonate
EP2539706A4 (en) ARYLPIPERAZONE ANTAGONISTS OF OPIOID RECEPTORS
EP2488186A4 (en) ANINEOPLASTIC USES OF ARTERINE ANTAGONISTS
GB0900754D0 (en) EP4 Receptor antagonists
GB0900755D0 (en) Ep4 receptor antagonists
GB0900756D0 (en) EP4 Receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120201

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1171946

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20130328

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20130322BHEP

Ipc: A61K 31/195 20060101AFI20130322BHEP

Ipc: A61P 17/02 20060101ALI20130322BHEP

Ipc: A61K 47/06 20060101ALI20130322BHEP

Ipc: A61P 17/00 20060101ALI20130322BHEP

Ipc: A61K 31/185 20060101ALI20130322BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131029

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1171946

Country of ref document: HK